Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer
Autore:
Eisenthal, A; Polyvkin, N; Bramante-Schreiber, L; Misonznik, F; Hassner, A; Lifschitz-Mercer, B;
Indirizzi:
Tel Aviv Sourasky Med Ctr, Inst Pathol, IL-64239 Tel Aviv, Israel Tel AvivSourasky Med Ctr Tel Aviv Israel IL-64239 4239 Tel Aviv, Israel Sapir Med Ctr, Dept Geriatr, Tel Aviv, Israel Sapir Med Ctr Tel Aviv Israel r Med Ctr, Dept Geriatr, Tel Aviv, Israel
Titolo Testata:
HUMAN PATHOLOGY
fascicolo: 8, volume: 32, anno: 2001,
pagine: 803 - 807
SICI:
0046-8177(200108)32:8<803:EODCIO>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
NECROSIS-FACTOR-ALPHA; CARCINOMA; MATURATION; MELANOMA; IMMUNOTHERAPY; MOLECULES;
Keywords:
dendritic cells; ovarian tumors; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Eisenthal, A Tel Aviv Sourasky Med Ctr, Inst Pathol, 6 Weizman St, IL-64239 Tel Aviv, Israel Tel Aviv Sourasky Med Ctr 6 Weizman St Tel Aviv Israel IL-64239
Citazione:
A. Eisenthal et al., "Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer", HUMAN PATH, 32(8), 2001, pp. 803-807

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells and arethought to reflect the interaction between the host immune system and tumor cells. In a retrospective study, we analyzed the presence of DCs and memory lymphocytes in tumor biopsy specimens of 18 patients with ovarian cancer. These patients were followed up for 10 to 37 months. Within this period, 9 patients had no evidence of disease (NED, group A), and 9 patients had recurrence (group B). In group A, 5 cases were stage III, 1 was stage 1, and I was stage II. In group B, 5 cases were stage III, 1 was stage III-IV, and3 were stage IV. Our results show that the mean number of cells expressingthe DC phenotype, HLA-DR+ CD1a(+), in tumor biopsies was substantially higher in group A than in group B (HIA-DR+: 37.8 +/- 18.2 v 10.7 +/- 2.2, respectively; P <.005; CD1a(+): 9.5 <plus/minus> 11.3 v 2.1 +/- 3.7). On the other hand, the number of cells expressing the DC phenotype S-100 protein wassubstantially lower in group A than in group B (S-100(+): 9.7 +/- 9.9 v 16.2 +/- 12.7), although the difference was not statistically significant. There was no difference in the number of tumor-infiltrating CD45RO(+) cells between groups A and B (CD45RO(+): 39.1 +/- 28.5 v 34.2 +/- 19.1). Our results show that the presence of relatively high numbers of defined DC subpopulations may have prognostic value in ovarian tumors. HUM PATHOL 32: 803-807. (C) 2001 by W.B. Saunders Company.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:07:23